Hepatic artery perfusion embolization generally refers to transarterial chemoembolization (TACE), which is a common clinical non-surgical treatment for hepatocellular carcinoma, with a wide range of indications for various kinds of patients, such as those who cannot tolerate surgery, those who have high risk factors for recurrence, and those with ruptured hepatocellular carcinoma. 1. TACE can be performed on patients with stage Ia, Ib, IIa who cannot tolerate surgery or have no desire for surgery although they have indications for surgery. 2. For patients with stage IIb, IIIa and some IIIb, liver function evaluation child-pughA/B grade, and activity status score 0-2 can be treated with TACE. 3. Patients with incomplete obstruction of the portal vein, or complete obstruction compensated by collateral circulation, or restoration of portal blood flow by stenting can undergo TACE. 4. Patients with bleeding from portal hypertension due to hepatic artery-portal vein shunt can be treated with TACE. 5. TACE can be performed to prevent recurrence in tumors with recurrent factors such as multiple tumors, naked eye or microscopic cancer embolism, palliative surgery, and tumor markers such as AFP that have not dropped to normal range after surgery. 6. For patients who have no chance of surgery at the beginning, TACE can be used to transform the tumor, downgrade the stage and win the chance of surgery. 7. Those with spontaneous rupture of liver cancer can also be treated with TACE. For patients diagnosed with liver cancer, they should immediately go to the relevant departments of regular hospitals for treatment under the guidance of specialized physicians to avoid delay.